Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury

Abstract

// Valentina Masola 1, 2 , Gloria Bellin 1, 3 , Gisella Vischini 4 , Luigi Dall’Olmo 5 , Simona Granata 1 , Giovanni Gambaro 1 , Antonio Lupo 1 , Maurizio Onisto 2 and Gianluigi Zaza 1 1 Renal Unit, Department of Medicine, University Hospital of Verona, Verona, Italy 2 University of Padova, Department of Biomedical Sciences, Padua, Italy 3 Maria Cecilia Hospital, GVM Care and Research, Cotignola, Ravenna, Italy 4 Università Cattolica del Sacro Cuore, Rome, Italy 5 Azienda Ulss 3 Serenissima-Ospedale San Giovanni e Paolo, Venice, Italy Correspondence to: Maurizio Onisto, email: maurizio.onisto@unipd.it Keywords: heparanase; fibrosis; chronic kidney disease; inflammation Received: June 19, 2018      Accepted: October 24, 2018      Published: November 16, 2018 ABSTRACT Renal ischemia/reperfusion (I/R) injury occurs in patients undergoing renal transplantation and with acute kidney injury and is responsible for the development of chronic allograft dysfunction as characterized by parenchymal alteration and fibrosis. Heparanase (HPSE), an endoglycosidase that regulates EMT and macrophage polarization, is an active player in the biological response triggered by ischemia/reperfusion (I/R) injury. I/R was induced in vivo by clamping left renal artery for 30 min in wt C57BL/6J mice. Animals were daily treated and untreated with Roneparstat (an inhibitor of HPSE) and sacrificed after 8 weeks. HPSE, fibrosis, EMT-markers, inflammation and oxidative stress were evaluated by biomolecular and histological methodologies together with the evaluation of renal histology and measurement of renal function parameters. 8 weeks after I/R HPSE was upregulated both in renal parenchyma and plasma and tissue specimens showed clear evidence of renal injury and fibrosis. The inhibition of HPSE with Roneparstat-restored histology and fibrosis level comparable with that of control. I/R-injured mice showed a significant increase of EMT, inflammation and oxidative stress markers but they were significantly reduced by treatment with Roneparstat. Finally, the inhibition of HPSE in vivo almost restored renal function as measured by BUN, plasma creatinine and albuminuria. The present study points out that HPSE is actively involved in the mechanisms that regulate the development of renal fibrosis arising in the transplanted organ as a consequence of ischemia/reperfusion damage. HPSE inhibition would therefore constitute a new pharmacological strategy to reduce acute kidney injury and to prevent the chronic pro-fibrotic damage induced by I/R.